UNION CITY, Calif., May 14, 2009 (GLOBE NEWSWIRE) -- Questcor Pharmaceuticals, Inc. (Nasdaq:QCOR) announced today that it will present at the Deutsche Bank 34th Annual Health Care Conference on Tuesday, May 19, 2009, at The InterContinental Boston. Don Bailey, President and CEO, will discuss the Company's business strategy and historical financial performance at 4:35 p.m. Eastern Time.

Attendance at the conference is by invitation only. A live audio webcast of Questcor's presentation may be accessed through the Company's website at www.questcor.com. An archived replay of the presentation will be available after the live presentation, and can also be accessed at www.questcor.com.

About Questcor

Questcor Pharmaceuticals, Inc. is a pharmaceutical company that markets two commercial products, H.P. Acthar(r) Gel ("Acthar") and Doral(r). Acthar (repository corticotropin injection) is an injectable drug that is approved for the treatment of certain disorders with an inflammatory component, including the treatment of exacerbations associated with multiple sclerosis ("MS") and to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythamatosus. In addition, Acthar is not indicated for, but is used in treating patients with infantile spasms ("IS"), a rare form of refractory childhood epilepsy, and opsoclonus myoclonus syndrome, a rare autoimmune-related childhood neurological disorder. Doral is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. For more information, please visit www.questcor.com.

CONTACT:  Questcor Pharmaceuticals, Inc.
          Don Bailey
          510-400-0776
          dbailey@Questcor.com
          EVC Group, Inc.
          Investors
          Doug Sherk
            415-896-6820
          Media
          Christopher Gale
            646-201-5431